EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy

Matthew V Cowley iD, Johanna Pruller, Massimo Ganassi iD, Peter S Zammit iD, Christopher R S Banerji iD

eLife · 2023

DOI: 10.7554/elife.88345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Matthew V Cowley und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Sustainable and Circular Technologies, Department of Chemistry, University of Bath, Bath, United Kingdom. Hauptthemen laut MEDLINE: Muscular Dystrophy, Facioscapulohumeral. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, EPSRC Centre for Doctoral Training in Sustainable Chemical Technologies, Friends of FSH Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Facioscapulohumeral muscular dystrophy (FSHD) is an incurable myopathy linked to the over-expression of the myotoxic transcription factor DUX4. Targeting DUX4 is the leading therapeutic approach, however, it is only detectable in 0.1–3.8% of FSHD myonuclei. How rare DUX4 drives FSHD and the optimal anti-DUX4 strategy are unclear. We combine stochastic gene expression with compartment models of cell states, building a simulation of DUX4 expression and consequences in FSHD muscle fibers. Investigating iDUX4 myoblasts, scRNAseq, and snRNAseq of FSHD muscle we estimate parameters including DUX4 mRNA degradation, transcription and translation rates, and DUX4 target gene activation rates. Our model accurately recreates the distribution of DUX4 and targets gene-positive cells seen in scRNAseq of FSHD myocytes. Importantly, we show DUX4 drives significant cell death despite expression in only 0.8% of live cells. Comparing scRNAseq of unfused FSHD myocytes to snRNAseq of fused FSHD myonuclei, we find evidence of DUX4 protein syncytial diffusion and estimate its rate via genetic algorithms. We package our model into freely available tools, to rapidly investigate the consequences of anti-DUX4 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, FacioscapulohumeralHumansHomeodomain ProteinsGene Expression RegulationGenes, HomeoboxMuscle Fibers, SkeletalMuscle, Skeletal

Stichwörter der Autor:innen

DUX4FSHDcell biologycellular automatoncomputational biologyfacioscapulohumeral muscular dystrophyhumanmusclestochastic gene expressionsystems biology

Substanzen

Homeodomain Proteins

Autor:innen und Institutionen

  • Centre for Sustainable and Circular Technologies, Department of Chemistry, University of Bath, Bath, United Kingdom.
  • King's College London, Randall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, London, United Kingdom.
  • The Alan Turing Institute, British Library, London, United Kingdom.

ORCID-Profile: Matthew V Cowley, Massimo Ganassi, Peter S Zammit, Christopher R S Banerji

Förderung

  • Medical Research Council
  • EPSRC Centre for Doctoral Training in Sustainable Chemical Technologies
  • Friends of FSH Research
  • Muscular Dystrophy UK
  • FSHD Society
  • Association Francaise contre les Myopathies
  • SOLVE FSHD
  • The Turing-Roche Partnership

Zitieren

APA

Cowley, M. V., Pruller, J., Ganassi, M., Zammit, P. S., & Banerji, C. R. S. (2023). An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy. eLife. https://doi.org/10.7554/elife.88345

Vancouver

Cowley MV, Pruller J, Ganassi M, Zammit PS, Banerji CRS. An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy. eLife. 2023. doi:10.7554/elife.88345

BibTeX
@article{Cowley2023,
  author = {Cowley, Matthew V and Pruller, Johanna and Ganassi, Massimo and Zammit, Peter S and Banerji, Christopher R S},
  title = {An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy},
  journal = {eLife},
  year = {2023},
  doi = {10.7554/elife.88345}
}
Kostenlos starten →